Obesity and body weight control

October 10, 2017

Natural product therapy for body weight control, energy homeostasis and TIIDM: A therapeutic mix encompassing Berberine, Leucine and Genistein (BLG) increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 10/October/2017,11.35 pm

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour […]
October 3, 2017

Molecular therapy for TIIDM and obesity-associated metabolic deficits: Milnacipran, a serotonin norepinephrine reuptake inhibitor,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 4/October/2017, 2.39 am

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that […]
September 26, 2017

Natural product-based therapy for TIIDM and obesity-associated metabolic deficits: Teasaponin, isolated from camellia sinesis, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 27/September/2017, 1.24 am

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that […]
September 26, 2017

Natural product-based therapy for TIIDM: A pharmaceutical mixture encompassing Fucosterol; EGCG; Scopoletin; Cholecalciferol; Celastrol (FESCC) augments the expression of FGF19 and FGF1,   attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIIDM via up regulation of its target gene, 26/September/2017, 9.15 pm

Introduction: What they say A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection […]